Hormone therapy in the 50s not linked to memory loss
Previous studies had shown that using hormones to alleviate menopause symptoms is linked with an increase in breast-cancer risk. The findings led to fewer hormone prescriptions for postmenopausal women, and a concurrent decrease in breast-cancer incidence shortly thereafter, which has been attributed to the reduced use of HRT, the researchers said. In the new study, in line with the previous findings , there was an overall link between HRT use and a higher rate of breast cancer. On average, 578 in 10,000 women who used HRT developed breast cancer, compared with 546 in 10,000 women who didn’t use HRT. The study has some limitations, the researchers said.
For the original version including any supplementary images or video, visit http://www.foxnews.com/health/2013/09/04/hormone-therapy-may-pose-higher-cancer-risk-in-some-women/
Hormone therapy, calcium may lower fracture risk
The group recommended against supplement use to prevent broken bones. For the new study, Jean Wactawski-Wende from the University at Buffalo and her colleagues compared seven years’ worth of fracture data for women in their 50s, 60s and 70s participating in the Women’s Health Initiative (WHI) study. In one arm of the trial, participants were randomly assigned to take either hormone therapy or a drug-free placebo. In another, they took 1,000 milligrams of calcium and 400 IU of vitamin D or placebo tablets each day. About 16,000 women were part of both the hormone and vitamin trials, including 4,000 randomized to both hormone therapy – either estrogen alone or estrogen and progesterone – and calcium and vitamin D. In total, 214 women had a hip fracture during the study. The researchers found that women assigned to both the hormone therapy and vitamin groups were about half as likely to have a fracture as those in the placebo groups.
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/06/28/us-hormone-therapy-idUSBRE95R0YN20130628
The women were assigned to take estrogen, estrogen and progesterone or a placebo for about seven years at the beginning of the study between 1996 and 1999. They were then followed for about the next 14 years. During the follow-up period, the women were asked 14 questions that measured their cognitive abilities during phone interviews. Overall, all groups scored about a 38 on a scale from zero to 50 – with lower scores signaling more memory problems. There was also no difference between the groups on several other scales that measured – among other things – attention and working memory.
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/06/26/us-hormone-therapy-idUSBRE95P1CT20130626